Physician profile
Sara E Suthers
NPI 1619936184
$2,341.01
in general payments reported to CMS, 2019-2025
52 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $103 · 2021: $125 · 2022: $393 · 2023: $858 · 2024: $481 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $199.96 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $176.78 | 2021-2024 | Myrisk |
| Astrazeneca Pharmaceuticals Lp | $146.18 | 2019-2023 | Enhertu, Imfinzi, Lynparza |
| Abbvie INC. | $125.38 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Molli Surgical (US) INC | $109.63 | 2023 | |
| Novartis Pharmaceuticals Corporation | $100.94 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $94.32 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $82.47 | 2020-2023 | Darzalex, Tecvayli, Carvykti |
| Amgen INC. | $77.42 | 2020-2022 | |
| Seagen INC. | $68.06 | 2021-2023 | Padcev, Tukysa |
| Tela Bio, INC. | $66.82 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Lilly USA, LLC | $61.33 | 2022-2024 | Retevmo, Jaypirca |
| Incyte Corporation | $56.63 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Motiva USA, LLC | $52.94 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $52.48 | 2023 | Libtayo |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Suthers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.